|
業務類別
|
Biotechnology |
|
業務概覽
|
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property. |
| 公司地址
| 55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7 |
| 電話號碼
| +1 844 978-3540 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.quantumbiopharma.com |
| 員工數量
| 7 |
| Dr. Andrzej Chruscinski |
Vice-President, Clinical and Scientific Affairs |
-- |
28/03/2025 |
| Dr. Ashwini Joshi |
Director, Pharmaceutical Development |
-- |
28/03/2025 |
| Mr. Zeeshan Saeed |
Chief Executive Officer, Co-Executive Chairman of the Board and President |
美元 218.64K |
28/03/2025 |
| Mr. Nathan Coyle |
Controller |
美元 93.97K |
28/03/2025 |
| Dr. Lakshmi P. Kotra |
Director, Chief Executive Officer, Lucid, President, FSD Biosciences and Chief Executive Officer, FSD Australia |
-- |
28/03/2025 |
| Mr. Donal Carroll |
Chief Financial Officer |
美元 218.64K |
28/03/2025 |
|
|
| Mr. Michael Zapolin |
Independent Director |
28/03/2025 |
| Mr. Adnan Bashir |
Independent Director |
28/03/2025 |
| Mr. Zeeshan Saeed |
Chief Executive Officer, Co-Executive Chairman of the Board and President |
28/03/2025 |
| Dr. Lakshmi P. Kotra |
Director, Chief Executive Officer, Lucid, President, FSD Biosciences and Chief Executive Officer, FSD Australia |
28/03/2025 |
| Mr. Anthony Durkacz |
Executive Co-Chairman of the Board |
28/03/2025 |
| Dr. Eric Hoskins |
Independent Director |
28/03/2025 |
| Mr. Terry Lynch |
Independent Director |
28/03/2025 |
|
|
|
|
